CSS LLC’s KalVista Pharmaceuticals KALV Stock Holding History

CSS LLC’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,000	Closed	-$72K	–	1238
2021 Q2	$72K	Sell	3,000 -17,500	-85%	-$458K	﹤0.01%	964
2021 Q1	$527K	Buy	+20,500	New	+$539K	0.02%	575

Other funds holding KALV

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

CSS LLC's KALV Position: Q1 2023 in Review

CSS LLC sold out of KalVista Pharmaceuticals (KALV) in Q1 2023, closing a stake of 10,056 shares — an estimated $68K sold.

CSS LLC first reported a position in KALV in Q4 2020 and held it in 9 quarters. The position peaked at $1.03M in Q1 2021. 88 funds tracked by Wall St. Rank hold KALV as of Q1 2023.

CSS LLC reported no remaining KalVista Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
CSS LLC sold 10,056 KalVista Pharmaceuticals shares in Q1 2023, an estimated $68K.
CSS LLC first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 9 quarters.
CSS LLC's KalVista Pharmaceuticals position peaked at $1.03M in Q1 2021.
88 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.